Pembrolizumab in High-risk Thyroid Cancer

Clinical trial NCT05852223 · RECRUITING

Trial details

NCT number: NCT05852223
Sponsor: Istituti Clinici Scientifici Maugeri SpA
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Differentiated Thyroid Cancer

Start date: 2024-12-20
Primary completion: 2026-11-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.